Tlwm Invests $264,000 in Natera, Inc. (NASDAQ:NTRA)

Tlwm purchased a new position in shares of Natera, Inc. (NASDAQ:NTRA) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 2,890 shares of the medical research company’s stock, valued at approximately $264,000.

Other institutional investors have also added to or reduced their stakes in the company. RiverPark Advisors LLC bought a new stake in shares of Natera during the fourth quarter worth about $27,000. Principal Securities Inc. purchased a new stake in shares of Natera in the fourth quarter worth approximately $32,000. Oliver Lagore Vanvalin Investment Group lifted its holdings in shares of Natera by 109.3% in the fourth quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 389 shares in the last quarter. CWM LLC boosted its position in shares of Natera by 41.8% during the fourth quarter. CWM LLC now owns 1,867 shares of the medical research company’s stock valued at $117,000 after buying an additional 550 shares during the last quarter. Finally, First Horizon Advisors Inc. grew its holdings in Natera by 36.1% during the fourth quarter. First Horizon Advisors Inc. now owns 2,089 shares of the medical research company’s stock worth $131,000 after buying an additional 554 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Natera

In other news, CEO Steven Leonard Chapman sold 6,816 shares of the company’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $93.13, for a total value of $634,774.08. Following the transaction, the chief executive officer now owns 227,710 shares of the company’s stock, valued at $21,206,632.30. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Natera news, insider Jonathan Sheena sold 1,000 shares of the company’s stock in a transaction that occurred on Thursday, April 25th. The stock was sold at an average price of $89.55, for a total value of $89,550.00. Following the completion of the sale, the insider now owns 69,082 shares of the company’s stock, valued at $6,186,293.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Steven Leonard Chapman sold 6,816 shares of the company’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $93.13, for a total transaction of $634,774.08. Following the sale, the chief executive officer now owns 227,710 shares of the company’s stock, valued at $21,206,632.30. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 184,665 shares of company stock valued at $17,732,033. Corporate insiders own 7.60% of the company’s stock.

Natera Stock Performance

Shares of NTRA stock traded down $1.38 during trading on Thursday, reaching $110.01. 949,496 shares of the company’s stock traded hands, compared to its average volume of 1,338,041. Natera, Inc. has a 1 year low of $36.90 and a 1 year high of $117.23. The company has a market capitalization of $13.51 billion, a P/E ratio of -35.26 and a beta of 1.52. The company has a current ratio of 4.12, a quick ratio of 3.98 and a debt-to-equity ratio of 0.36. The firm’s 50-day moving average is $104.06 and its 200 day moving average is $85.27.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, May 9th. The medical research company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.16. The firm had revenue of $367.70 million for the quarter, compared to the consensus estimate of $316.31 million. Natera had a negative return on equity of 49.72% and a negative net margin of 30.24%. The business’s quarterly revenue was up 52.1% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.23) earnings per share. Equities research analysts expect that Natera, Inc. will post -2.43 EPS for the current year.

Analyst Ratings Changes

NTRA has been the topic of several recent analyst reports. Sanford C. Bernstein upgraded Natera from a “market perform” rating to an “outperform” rating and set a $120.00 price objective on the stock in a research note on Friday, April 5th. TD Cowen raised their price target on shares of Natera from $123.00 to $137.00 and gave the company a “buy” rating in a research report on Friday, May 10th. Robert W. Baird increased their price objective on shares of Natera from $99.00 to $117.00 and gave the company an “outperform” rating in a research note on Friday, May 10th. Jefferies Financial Group initiated coverage on shares of Natera in a research report on Monday, June 3rd. They set a “buy” rating and a $142.00 target price on the stock. Finally, Craig Hallum assumed coverage on Natera in a report on Monday, April 8th. They issued a “buy” rating and a $117.00 target price for the company. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $101.19.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.